McLeod myopathy revisited: more neurogenic and less benign (original) (raw)

Journal Article

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

,

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

1Institute of Neuropathology, University Hospital Zürich, Switzerland, 2Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany, 3Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität, München, Germany, 4Clinica Las Condes, Santiago, Chile, 5Institute of Neuropathology, University of New Mexico, Albuquerque, New Mexico, USA, 6Parkinsonklinik, Bad Nauheim, Germany, 7Department of Neuropathology, Johannes Gutenberg University, Mainz, Germany and 8Department of Neurology, University Hospital Zürich, Switzerland

Search for other works by this author on:

Revision received:

05 October 2007

Accepted:

12 October 2007

Published:

01 December 2007

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Ekkehard Hewer, Adrian Danek, Benedikt G. Schoser, Marcelo Miranda, Ross Reichard, Claudia Castiglioni, Matthias Oechsner, Hans H. Goebel, Frank L. Heppner, Hans H. Jung, McLeod myopathy revisited: more neurogenic and less benign, Brain, Volume 130, Issue 12, December 2007, Pages 3285–3296, https://doi.org/10.1093/brain/awm269
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

The X-linked McLeod neuroacanthocytosis syndrome (MLS) has originally been denoted as ‘benign’ McLeod myopathy. We assessed the clinical findings and the muscle pathology in the eponymous index patient, Hugh McLeod, and in nine additional MLS patients. Only one patient had manifested with neuromuscular symptoms. During a mean follow-up of 15 years, however, eight patients including the initial index patient showed elevated skeletal muscle creatine kinase levels ranging from 300 to 3000 U/L, and had developed muscle weakness and atrophy. Two patients had disabling leg weakness. Muscle histology was abnormal in all 10 patients. Clear but unspecific myopathic changes were found in only four patients. All patients, however, had neurogenic changes of variable degree. Post-mortem motor and sensory nerve examinations support the view that muscle atrophy and weakness are predominantly due to an axonal motor neuropathy rather than to a primary myopathy. Multisystem manifestations developed in eight patients at a mean age of 39 years. Three patients manifested with psychiatric features comprising schizophrenia-like psychosis and personality disorder, two presented with generalized seizures and one with chorea. During follow-up, seven patients developed chorea, six had psychiatric disorders, five had cognitive decline and three had generalized seizures. Five patients died because of MLS-related complications including sudden cardiac death, chronic heart failure and pneumonia between 55 and 69 years. In conclusion, our findings confirm that MLS is not a benign condition but rather a progressive multisystem disorder sharing many features with Huntington's disease.

© The Author (2007). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Topic:

• chronic heart failure
• sudden cardiac death
• chorea
• huntington's disease
• asthenia
• atrophy
• follow-up
• mental disorders
• muscle weakness
• skeletal muscles
• muscular atrophy
• myopathy
• neurons
• personality disorders
• pneumonia
• psychiatry
• psychotic disorders
• schizophrenia
• creatine kinase measurement
• histology
• pathology
• cognitive impairment
• generalized seizures
• x-linked inheritance
• neuritis, motor
• sensory nerves
• chorea acanthocytosis syndrome
• lower extremity paresis
• multisystem disorders

You do not currently have access to this article.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

McLeod myopathy revisited: more neurogenic and less benign - 24 Hours access

EUR €51.00

GBP £44.00

USD $55.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 2,569

1,418 Pageviews

1,151 PDF Downloads

Since 12/1/2016

Citations

39 Web of Science

×

Email alerts

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic